SCHEMBL8036031

SCHEMBL8036031

CC1(Br)C=CC=CC1(C)Br

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31319920 0.77
SCHEMBL21247921 0.65
SCHEMBL6666128 0.64
SCHEMBL2357367 0.64
SCHEMBL16160994 0.64
SCHEMBL1982688 0.64
SCHEMBL35210236 0.64
SCHEMBL24243502 0.61
SCHEMBL1261763 0.58
SCHEMBL6915854 0.58

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4727653-A1 DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF Mariana Oncology Inc. (US) 2026-04-22 EP disclosed
EP-4727655-A1 DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF Mariana Oncology Inc. (US) 2026-04-22 EP disclosed
EP-4727654-A1 DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF Mariana Oncology Inc. (US) 2026-04-22 EP disclosed
US-20260077017-A1 ADRENOMEDULLIN ANALOGS AND METHODS OF USE THEREOF UNIV LELAND STANFORD JUNIOR (US) 2026-03-19 US disclosed
US-20250296959-A1 B7-H3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF MARIANA ONCOLOGY INC (US) 2025-09-25 US disclosed
US-20250205373-A1 ENRICHED AND STABLE RADIOLIGAND THERAPY FORMULATIONS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME MARIANA ONCOLOGY INC (US) 2025-06-26 US disclosed
US-20250186541-A1 DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF MARIANA ONCOLOGY INC (US) 2025-06-12 US disclosed
WO-2025122615-A1 ENRICHED AND STABLE RADIOLIGAND THERAPY FORMULATIONS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME MARIANA ONCOLOGY INC. (US) 2025-06-12 WO disclosed
EP-4565258-A2 COMPOSITIONS FOR THE TREATMENT OF DISEASE Sightstream Biotherapeutics, Inc. (US) 2025-06-11 EP disclosed
US-20250179691-A1 MULTIVALENT GLYCOPEPTIDES THAT TIGHTLY BIND TO CARBOHYDRATE-BINDING MONOCLONAL ANTIBODY FAMILY PGT128 BRANDEIS UNIVERSITY (US) 2025-06-05 US disclosed
US-20170137468-A1 MODULATION OF COMPLEMENT ACTIVITY UCB HOLDINGS, INC. 2017-05-18 US disclosed
EP-3154561-A2 MODULATION OF COMPLEMENT ACTIVITY RA Pharmaceuticals, Inc. (US) 2017-04-19 EP disclosed
WO-2016123371-A1 MODULATORS OF COMPLEMENT ACTIVITY RA PHARMACEUTICALS, INC. (US) 2016-08-04 WO disclosed
WO-2015191951-A2 MODULATION OF COMPLEMENT ACTIVITY RA PHARMACEUTICALS, INC. (US) 2015-12-17 WO disclosed
US-6046197-A NON-PEPTIDE AMIDE COMPOUNDS; STIMULATE HEMATOPOIESIS AND MAY BE USEFUL FOR TREATMENT OF VIRAL, FUNGAL AND BACTERIAL INFECTIOUS DISEASES SMITHKLINE BEECHAM CORPORATION (US) 2000-04-04 US disclosed
EP-0989136-A1 PEPTIDES HAVING CYCLIC STRUCTURES AND EXERTING P53 PROTEIN ACTIVTY-RESTORING EFFECT ON P53 PROTEIN MUTANTS KYOWA HAKKO KOGYO CO., LTD. (JP) 2000-03-29 EP disclosed
US-5530139-A BENZO- AND NAPHTHOTHIOPHENE COMPOUNDS; INTERMEDIATES IN AGRICULTURE, FOODS AND MEDICINE, MONOMER FOR ELECTROCONDUCTIVE POLYMER SHOWA DENKO KABUSHIKI KAISHA (JP) 1996-06-25 US disclosed
EP-0421436-A2 Substituted carboxytetrahydroisoquinolines and derivatives thereof having pharmaceutical activity WARNER-LAMBERT COMPANY (US) 1991-04-10 EP disclosed
US-4925770-A COATING, PRIOR TO LIGHT EXPOSURE OF PHOTORESIST LAYER, A PHOTO-BLEACHABLE COMPOUND AND A WATER SOLUBLE POLYMER DIRECTOR GENERAL OF AGENCY OF INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) 1990-05-15 US disclosed
EP-0246885-A2 A contrast-enhancing agent for photolithography Japan as represented by Director-General, Agency of Industrial Science and Technology (JP) 1987-11-25 EP disclosed